Published in Genes Dev on April 14, 2003
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05
Hippo signaling: growth control and beyond. Development (2011) 5.25
The Hippo pathway and human cancer. Nat Rev Cancer (2013) 5.17
Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol (2006) 3.95
Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev (2010) 3.77
Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol (2007) 2.89
E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc Natl Acad Sci U S A (2011) 2.61
A crucial role of WW45 in developing epithelial tissues in the mouse. EMBO J (2008) 2.46
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell (2010) 2.38
Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res (2008) 2.18
Deconstructing the skin: cytoarchitectural determinants of epidermal morphogenesis. Nat Rev Mol Cell Biol (2011) 1.94
Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells. J Cell Biol (2010) 1.92
Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane. J Cell Biol (2005) 1.86
A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell (2011) 1.86
The Drosophila tumor suppressors Expanded and Merlin differentially regulate cell cycle exit, apoptosis, and Wingless signaling. Dev Biol (2006) 1.85
E-cadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling independently of other cell interactions. Mol Biol Cell (2007) 1.84
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol (2009) 1.78
Molecular components of the adherens junction. Biochim Biophys Acta (2008) 1.78
The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex. Dev Cell (2010) 1.67
Merlin/ERM proteins establish cortical asymmetry and centrosome position. Genes Dev (2012) 1.60
The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol (2005) 1.60
Merlin and the ERM proteins--regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol (2009) 1.54
Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer (2012) 1.44
Salvador-Warts-Hippo pathway in a developmental checkpoint monitoring helix-loop-helix proteins. Dev Cell (2015) 1.42
Localization to the cortical cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor receptor silencing. Mol Cell Biol (2007) 1.42
Domains controlling cell polarity and proliferation in the Drosophila tumor suppressor Scribble. J Cell Biol (2004) 1.41
Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis (2007) 1.34
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med (2014) 1.34
Nf2/Merlin: a coordinator of receptor signalling and intercellular contact. Br J Cancer (2007) 1.30
Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. EMBO Rep (2012) 1.30
The hippo pathway is activated and is a causal mechanism for adipogenesis in arrhythmogenic cardiomyopathy. Circ Res (2013) 1.30
Growth control by committee: intercellular junctions, cell polarity, and the cytoskeleton regulate Hippo signaling. Dev Cell (2012) 1.26
Cell polarity proteins: common targets for tumorigenic human viruses. Oncogene (2008) 1.22
Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival. Curr Protein Pept Sci (2010) 1.21
The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion. Proc Natl Acad Sci U S A (2007) 1.17
Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry (2004) 1.13
Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function. Proc Natl Acad Sci U S A (2011) 1.13
Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma. Proc Natl Acad Sci U S A (2009) 1.10
Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway. Cell Res (2015) 1.09
Protein kinase A activity and anchoring are required for ovarian cancer cell migration and invasion. PLoS One (2011) 1.08
The regulation of organ size in Drosophila: physiology, plasticity, patterning and physical force. Organogenesis (2010) 1.07
Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol (2011) 1.04
Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett (2014) 1.03
Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways. Neoplasia (2011) 1.02
A role for the retinoblastoma protein as a regulator of mouse osteoblast cell adhesion: implications for osteogenesis and osteosarcoma formation. PLoS One (2010) 1.02
The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol (2008) 1.01
PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. Exp Neurol (2009) 1.00
Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivators. Development (2013) 1.00
Update on meningiomas. Oncologist (2011) 0.99
Cellular expression profile for interstitial cells of cajal in bladder - a cell often misidentified as myocyte or myofibroblast. PLoS One (2012) 0.98
NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation. Oncogene (2010) 0.97
Nf2/merlin regulates hematopoietic stem cell behavior by altering microenvironmental architecture. Cell Stem Cell (2008) 0.97
Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromes. Acta Neuropathol (2011) 0.95
Rac1 controls Schwann cell myelination through cAMP and NF2/merlin. J Neurosci (2012) 0.94
Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis (2007) 0.94
Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity. Mutat Res (2007) 0.93
Out, in and back again: PtdIns(4,5)P(2) regulates cadherin trafficking in epithelial morphogenesis. Biochem J (2009) 0.91
Signaling from the adherens junction. Subcell Biochem (2012) 0.89
Merlin is a negative regulator of human melanoma growth. PLoS One (2012) 0.89
A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas. Front Oncol (2015) 0.88
The role of Drosophila Merlin in spermatogenesis. BMC Cell Biol (2008) 0.87
In vitro antisense therapeutics for a deep intronic mutation causing Neurofibromatosis type 2. Eur J Hum Genet (2012) 0.87
Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressor. Protein Sci (2011) 0.87
A cell motility screen reveals role for MARCKS-related protein in adherens junction formation and tumorigenesis. PLoS One (2009) 0.86
Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. Neuro Oncol (2014) 0.85
Role of Merlin/NF2 inactivation in tumor biology. Oncogene (2015) 0.85
Back to the future: proceedings from the 2010 NF Conference. Am J Med Genet A (2010) 0.84
FERM domain phosphoinositide binding targets merlin to the membrane and is essential for its growth-suppressive function. Mol Cell Biol (2011) 0.84
Impaired formation of homotypic cell-in-cell structures in human tumor cells lacking alpha-catenin expression. Sci Rep (2015) 0.83
The tumor suppressor merlin is required for cell cycle exit, terminal differentiation, and cell polarity in the developing murine lens. Invest Ophthalmol Vis Sci (2010) 0.83
The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications. Oncotarget (2015) 0.80
Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies. Acta Otorhinolaryngol Ital (2016) 0.79
Merlin/NF2 Suppresses Pancreatic Tumor Growth and Metastasis by Attenuating the FOXM1-Mediated Wnt/β-Catenin Signaling. Cancer Res (2015) 0.79
A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. Oncotarget (2015) 0.79
Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells. Brain (2013) 0.79
NF2/Merlin mediates contact-dependent inhibition of EGFR mobility and internalization via cortical actomyosin. J Cell Biol (2015) 0.79
Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer. Oncotarget (2016) 0.77
Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator. Anticancer Res (2013) 0.76
Epidermal polarity genes in health and disease. Cold Spring Harb Perspect Med (2014) 0.76
A splicing variant of Merlin promotes metastasis in hepatocellular carcinoma. Nat Commun (2015) 0.76
Ezrin: a regulator of actin microfilaments in cell junctions of the rat testis. Asian J Androl (2015) 0.76
Yes-associated protein impacts adherens junction assembly through regulating actin cytoskeleton organization. Am J Physiol Gastrointest Liver Physiol (2016) 0.75
Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. EBioMedicine (2017) 0.75
Using the neurofibromatosis tumor predisposition syndromes to understand normal nervous system development. Scientifica (Cairo) (2014) 0.75
THE RETINOBLASTOMA PROTEIN: A MASTER TUMOR SUPPRESSOR ACTS AS A LINK BETWEEN CELL CYCLE AND CELL ADHESION. Cell Health Cytoskelet (2014) 0.75
Frequency of loss of heterozygosity of the NF2 gene in schwannomas from Croatian patients. Croat Med J (2012) 0.75
The Retinoblastoma Tumor Suppressor Transcriptionally Represses Pak1 in Osteoblasts. PLoS One (2015) 0.75
Loss of Merlin induces metabolomic adaptation that engages dependence on Hedgehog signaling. Sci Rep (2017) 0.75
Merlin inhibits Wnt/β-catenin signaling by blocking LRP6 phosphorylation. Cell Death Differ (2016) 0.75
Influence of Membrane Receptor Lateral Diffusion on the Short-Term Depression of Acetylcholine-Induced Current in Helix Neurons. Cell Mol Neurobiol (2017) 0.75
Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and its Prognostic Impact on Tumour Growth Patterns. Sci Rep (2017) 0.75
Rho GTPases and the actin cytoskeleton. Science (1998) 28.19
A progression puzzle. Nature (2002) 9.56
ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol (2002) 8.41
Directed actin polymerization is the driving force for epithelial cell-cell adhesion. Cell (2000) 8.13
Mechanisms of epithelial cell-cell adhesion and cell compaction revealed by high-resolution tracking of E-cadherin-green fluorescent protein. J Cell Biol (1998) 5.03
Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin. Cell (2001) 5.01
Sticky business: orchestrating cellular signals at adherens junctions. Cell (2003) 4.91
NF1 tumor suppressor gene function: narrowing the GAP. Cell (2001) 4.11
Actin cable dynamics and Rho/Rock orchestrate a polarized cytoskeletal architecture in the early steps of assembling a stratified epithelium. Dev Cell (2002) 4.01
The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev (2001) 3.65
Spatio-temporal regulation of Rac1 localization and lamellipodia dynamics during epithelial cell-cell adhesion. Dev Cell (2002) 3.60
Cell-to-cell adherens junction formation and actin filament organization: similarities and differences between non-polarized fibroblasts and polarized epithelial cells. J Cell Sci (1995) 3.27
Cytoplasmic regulation of the movement of E-cadherin on the free cell surface as studied by optical tweezers and single particle tracking: corralling and tethering by the membrane skeleton. J Cell Biol (1998) 3.23
The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell (2001) 2.89
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev (2000) 2.72
Rho-family GTPases in cadherin-mediated cell-cell adhesion. Nat Rev Mol Cell Biol (2001) 2.68
Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev (1998) 2.66
Direct cadherin-activated cell signaling: a view from the plasma membrane. J Cell Biol (2002) 2.33
Mechanism for transition from initial to stable cell-cell adhesion: kinetic analysis of E-cadherin-mediated adhesion using a quantitative adhesion assay. J Cell Biol (1996) 2.20
Molecular architecture of adherens junctions. Curr Opin Cell Biol (2001) 1.94
The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Mol Cell Biol Res Commun (1999) 1.88
Dynamics of ligand-induced, Rac1-dependent anchoring of cadherins to the actin cytoskeleton. J Cell Biol (2002) 1.84
Cell adhesion in tumor invasion and metastasis: loss of the glue is not enough. Biochim Biophys Acta (2001) 1.72
The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev (1997) 1.67
Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev (2003) 1.64
Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci (2002) 1.59
Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localization. J Cell Biol (1998) 1.58
Distinct cellular and subcellular patterns of expression imply distinct functions for the Drosophila homologues of moesin and the neurofibromatosis 2 tumor suppressor, merlin. J Cell Biol (1996) 1.56
Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. J Biol Chem (1998) 1.54
Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev (2002) 1.43
Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene (1998) 1.38
Dynamics of contacts between lamellae of fibroblasts: essential role of the actin cytoskeleton. Proc Natl Acad Sci U S A (1998) 1.34
Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesionand spreading. Hum Mol Genet (1999) 1.27
Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet (1998) 1.25
Cellular transformation by a FERM domain mutant of the Nf2 tumor suppressor gene. Oncogene (2002) 1.23
Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nat Genet (2002) 1.22
Expression level, subcellular distribution and rho-GDI binding affinity of merlin in comparison with Ezrin/Radixin/Moesin proteins. Oncogene (1999) 1.22
The neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the filaments through a lateral association. Biochem J (2001) 1.15
Establishment of the circumferential actin filament network is a prerequisite for localization of the cadherin-catenin complex in epithelial cells. Cell Growth Differ (1999) 1.04
Merlin, the neurofibromatosis type 2 gene product, and beta1 integrin associate in isolated and differentiating Schwann cells. J Neurobiol (1998) 0.99
Molecular insights into neurofibromatosis 2. Neurobiol Dis (1997) 0.89
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol (2010) 5.05
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47
Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev (2010) 3.77
Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin. Genes Dev (2005) 3.59
Live imaging of stem cell and progeny behaviour in physiological hair-follicle regeneration. Nature (2012) 3.53
Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis. Cell (2003) 3.36
Ezrin is essential for epithelial organization and villus morphogenesis in the developing intestine. Dev Cell (2004) 3.33
Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol (2007) 2.89
A critical role for peptidoglycan N-deacetylation in Listeria evasion from the host innate immune system. Proc Natl Acad Sci U S A (2007) 2.46
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell (2010) 2.38
Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci U S A (2003) 2.16
DOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell (2003) 1.94
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J (2004) 1.85
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest (2012) 1.83
Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers. Lab Invest (2004) 1.82
Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience. Leuk Lymphoma (2009) 1.80
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A (2013) 1.72
Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res (2007) 1.71
The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex. Dev Cell (2010) 1.67
Merlin/ERM proteins establish cortical asymmetry and centrosome position. Genes Dev (2012) 1.60
Transfusions at home in patients with myelodysplastic syndromes. Leuk Res (2012) 1.59
β-Catenin activation regulates tissue growth non-cell autonomously in the hair stem cell niche. Science (2014) 1.55
Tissue-specific conditional CCM2 knockout mice establish the essential role of endothelial CCM2 in angiogenesis: implications for human cerebral cavernous malformations. Dis Model Mech (2009) 1.49
Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene (2002) 1.45
Bioluminescence imaging of live infected salmonids reveals that the fin bases are the major portal of entry for Novirhabdovirus. J Virol (2006) 1.45
Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer (2012) 1.44
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest (2009) 1.44
Ezrin and moesin function together to promote T cell activation. J Immunol (2009) 1.44
Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev (2002) 1.43
Localization to the cortical cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor receptor silencing. Mol Cell Biol (2007) 1.42
Anticoagulant and Anti-thrombotic Treatments in the Management of Hematological Malignancies in a Home Care Program. Indian J Palliat Care (2011) 1.42
CARD15/NOD2 is required for Peyer's patches homeostasis in mice. PLoS One (2007) 1.41
Murine Nod1 but not its human orthologue mediates innate immune detection of tracheal cytotoxin. EMBO Rep (2005) 1.41
Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med (2009) 1.41
A mouse model recapitulating molecular features of human mesothelioma. Cancer Res (2005) 1.39
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol (2008) 1.34
Ezrin...a metastatic detERMinant? Cancer Cell (2004) 1.33
Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res (2004) 1.31
Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res (2010) 1.24
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A (2011) 1.24
Making quality of life assessment a dashboard for patient management. Support Care Cancer (2014) 1.23
Cre-mediated germline mosaicism: a new transgenic mouse for the selective removal of residual markers from tri-lox conditional alleles. Nucleic Acids Res (2003) 1.21
Pain and anxiety associated with bone marrow aspiration and biopsy: a prospective study on 152 Italian patients with hematological malignancies. Ann Hematol (2011) 1.15
Microvilli defects in retinas of ezrin knockout mice. Exp Eye Res (2005) 1.14
WNT signaling increases proliferation and impairs differentiation of stem cells in the developing cerebellum. Development (2012) 1.12
Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system. Neuron (2003) 1.12
Magnetic cell sorting for enriching Schwann cells from adult mouse peripheral nerves. J Neurosci Methods (2003) 1.10
Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma. Proc Natl Acad Sci U S A (2009) 1.10
Home care management of patients affected by hematologic malignancies: a review. Haematologica (2006) 1.10
Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood (2008) 1.07
Disability and physical rehabilitation in patients with advanced hematological malignancies followed in a home care program. Support Care Cancer (2009) 1.05
Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res (2010) 1.04
A novel alpha(v)beta (3)-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis. Clin Exp Metastasis (2007) 1.02
Characterization of the axon initial segment (AIS) of motor neurons and identification of a para-AIS and a juxtapara-AIS, organized by protein 4.1B. BMC Biol (2011) 1.02
The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol (2008) 1.01
Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy. Nat Neurosci (2013) 1.01
Tumor suppressor Nf2 limits expansion of the neural progenitor pool by inhibiting Yap/Taz transcriptional coactivators. Development (2013) 1.00
Ezrin-mediated apical integrity is required for intestinal homeostasis. Proc Natl Acad Sci U S A (2011) 0.99
Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway. J Biol Chem (2002) 0.98
Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene (2003) 0.98
Protein 4.1B contributes to the organization of peripheral myelinated axons. PLoS One (2011) 0.98
Mouse models of neurofibromatosis 1 and 2. Neoplasia (2002) 0.98
Nf2/merlin regulates hematopoietic stem cell behavior by altering microenvironmental architecture. Cell Stem Cell (2008) 0.97
Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Hum Gene Ther (2006) 0.97
Nod2 mediates susceptibility to Yersinia pseudotuberculosis in mice. PLoS One (2008) 0.97
NOD2: a potential target for regulating liver injury. Lab Invest (2008) 0.95
Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. Eur J Cancer (2009) 0.95
Novel features of boundary cap cells revealed by the analysis of newly identified molecular markers. Glia (2009) 0.95
Familial adenomatous polyposis-associated desmoids display significantly more genetic changes than sporadic desmoids. PLoS One (2011) 0.94
Long-lasting remission induced by rituximab in two cases of refractory autoimmune haemolytic anaemia due to cold agglutinins. Blood Transfus (2009) 0.94
Tumor-suppression functions of merlin are independent of its role as an organizer of the actin cytoskeleton in Schwann cells. J Cell Sci (2009) 0.92
The tumor suppressor merlin interacts with microtubules and modulates Schwann cell microtubule cytoskeleton. Hum Mol Genet (2007) 0.91
Management of hematological malignancies in patients affected by renal failure. Expert Rev Anticancer Ther (2011) 0.91
Motor disability, clinical complications, quality of life, and survival in patients with cancer: a plausible scenario. Support Care Cancer (2014) 0.91
Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma. Cell Cycle (2005) 0.89
Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression. Sci Signal (2011) 0.89
Pure red cell aplasia associated with hemolytic anemia refractory to standard measures and resolved by rituximab in an elderly patient. Int J Hematol (2008) 0.89
Tumor suppressor schwannomin/merlin is critical for the organization of Schwann cell contacts in peripheral nerves. J Neurosci (2008) 0.88
Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. Brain Pathol (2007) 0.88
Association of Caspr/paranodin with tumour suppressor schwannomin/merlin and beta1 integrin in the central nervous system. J Neurochem (2003) 0.87
Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome. Blood Res (2013) 0.87
The use of major analgesics in patients with renal dysfunction. Curr Drug Targets (2010) 0.87
Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the merlin tumor suppressor. Protein Sci (2011) 0.87
Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet (2002) 0.86
Synergy of Nf2 and p53 mutations in development of malignant tumours of neural crest origin. Oncogene (2004) 0.85
Back to the future: proceedings from the 2010 NF Conference. Am J Med Genet A (2010) 0.84